1019 GMT - Novo Nordisk's diabetes treatment Ozempic faces falling sales amid U.S. share loss and price declines, Intron Health analysts write. "New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of [group] 2025 guidance on sales and EBIT." Intron Helath is 40% below 2030 consensus Ozempic sales, which could translate to a 16% cut to 2030 consensus group EBIT. The analysts suggest a profit warning is possible at or before first quarter results on May 7. However, results from a trial testing semaglutide as a treatment for Alzheimer's due this year "could be game changing." Intron Helath downgrades Novo to sell from buy and lowers its target price to 460 Danish kroner from 880 kroner. Shares fall 2.6% to 515.00 kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 24, 2025 06:19 ET (10:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.